Hyperactive CDK2 Activity in Basal-like Breast Cancer Imposes a Genome Integrity Liability that can be Exploited by Targeting DNA Polymerase Epsilon
Published: 27 October 2020| Version 1 | DOI: 10.17632/xvgb9rg7b7.1
Contributor:
Richard PossematoDescription
Data from "Hyperactive CDK2 Activity in Basal-like Breast Cancer Imposes a Genome Integrity Liability that can be Exploited by Targeting DNA Polymerase Epsilon"
Files
Categories
Primary Data